Just caught wind of some interesting news coming out of the vision correction space. STAAR Surgical got FDA clearance to expand the age range for its EVO Visian ICL procedure - that's the Implantable Collamer Lens for those wondering what icl meaning refers to in medical device circles. They're now approved to treat patients up to age 60 instead of just 45. Pretty significant move.

What caught my attention is the underlying data. The approval is backed by three years of FDA clinical trial results from 629 eyes, showing a solid safety profile. We're talking 1.25 safety index at year three, zero cases of pupillary block or pigment dispersion, and only a 0.16% rate of anterior subcapsular cataracts. Those are the kinds of numbers that get surgeons comfortable recommending a procedure.

Here's where it gets interesting from a market perspective. Real-world adoption data from 19 US refractive practices shows EVO ICL being used in over 70% of procedures for high myopia cases (patients with -8.0 diopters and above). Meanwhile, laser-based LASIK procedures have tanked - down nearly 40% over the past three years. Patient surveys show 53% of US vision correction consumers are now looking at alternatives to LASIK.

The numbers suggest there's a real shift happening. Management estimates 24 million myopic adults in the US could be candidates, including 8 million in that newly approved 46-60 age bracket. In international markets where the 46-60 segment has been available longer, it represents about 6% of their total EVO ICL patient base.

Stock-wise, STAA popped 8.4% on the announcement. Over six months though, it's down 37.2%, which puts it underwater against both the broader medical industry and the S&P 500. Current market cap is sitting around $805.82 million. The long-term case seems solid though - as LASIK demand continues declining and more patients opt for lens-based alternatives like ICL procedures, volumes should keep climbing.

One other note: the company recently appointed Warren Foust and Deborah Andrews as interim co-CEOs effective February 1st while the board searches for a permanent CEO. That's worth keeping an eye on as leadership transitions tend to create some uncertainty.

The broader intraocular lens market is valued around $5.34 billion as of 2026 with expected 4.72% annual growth through 2035, so there's real market expansion happening here. Worth monitoring if you follow the medical device space.